Medline (MDLN)
Financials 
Technical Analysis 
May 28, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Medline's IPO performance has shown promising growth, currently up 39.4% since its debut, indicating strong market interest despite being off its peak. The company reported a net sales growth of 9.8% and an adjusted EBITDA margin of 12.9% for the first nine months of 2025. Its financial health appears stable, though its balance sheet has room for improvement, leading to a cautious outlook on its valuation. Potential investors should be aware that existing shareholders maintain significant voting power, holding 80% of the votes, which may affect future company decisions. Despite the stock's current 41% jump above the offering price and a high PE ratio of approximately 45x for its growth rate, experts suggest waiting for a more favorable entry point around $29-30.
It went public today. Through the first 9 months of 2025: 9.8% net sales growth and 12.9% adjusted EBITDA margin. Boasts sold revenue growth in recent years and has a decent, not great, balance sheet. Those buying shares today will have little voting power while existing shareholders will hold 80% of the vote. Today, shares closed +41% above the offers price, so the share price is rich. Trades at roughly 45x PE, which is high for low double-digit growth. Likes this, but buy at $29-30.
- «
- ‹
- 1
- ›
- »
Medline (MDLN) Frequently Asked Questions
What is Medline stock symbol?
Medline is a OTC stock, trading under the symbol MDLN (previously MDLN-Q on Stockchase) on the (). It is usually referred to as or MDLN
Is Medline a buy or a sell?
In the last year, 2 stock analysts published opinions about MDLN (previously MDLN-Q on Stockchase). 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY on WEAKNESS. Read the latest stock experts' ratings for Medline .
Is Medline a good investment or a top pick?
Medline was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Medline .
Why is Medline stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Medline worth watching?
In the last year, there was no coverage of Medline published on Stockchase.
Is up 39.4% since its IPO last month. Though off its highs, it looks healthy and is better than many IPOs last year.